Learn more about COVID-19 in Saskatchewan:

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.


Released on August 9, 2012

After a thorough review, the Saskatchewan Ministry of Health has approved coverage of a new drug for a three-year old Langenburg resident who has a rare enzyme deficiency condition called mucopolysaccharidosis VI (MPS VI). The request to cover Naglazyme was received by the Saskatchewan Drug Plan on July 9, 2012.

The coverage decision took into consideration the drug's clinical effectiveness, cost and safety implications.

Individuals with MPS VI lack an enzyme which leads to the accumulation of complex sugar molecules that can result in complications such as skeletal deformities, joint disease, eye disease and cardiopulmonary disease.

While there is no known cure for MPS VI, Naglazyme (galsulfase), an enzyme replacement therapy, is designed to provide patients with a synthetic version of the enzyme they are lacking by infusing small doses into the patient's bloodstream on a weekly basis. To date, there are nine confirmed cases of MPS VI in Canada.

Coverage of the medication is approved on a case-by-case basis, and will cost between $250,000 and $300,000 annually for this patient.


For more information, contact:

Tyler McMurchy
Phone: 306-787-4083
Email: tmcmurchy@health.gov.sk.ca

We need your feedback to improve saskatchewan.ca. Help us improve